24On 14 January 2010, a pre-submission meeting took place between the EMA and the applicant concerning the application for marketing authorisation for Dexdor. At that meeting, the applicant reiterated that, in its view, the Czech marketing authorisation for Precedex did not comply with EU law, with the result that Precedex was not eligible as a reference medicinal product, within the meaning of Article 10(1) and (2)(a) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), as amended by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 (OJ 2004 L 136, p. 34), for a generic medicinal product within the meaning of Article 10(2)(b) of that directive. The applicant also stated that it intended to surrender the Czech marketing authorisation for Precedex as soon as it received it. The EMA replied that, if a party wished to dispute an existing marketing authorisation, it had to do so in court when the application for marketing authorisation for a generic medicinal product was submitted.